Clinical study of inhaled ambroxol in the adjunctive treatment of lower respiratory tract infection induced by Pseudomonas aeruginosa

OBJECTIVE To evaluate the efficacy and safety of inhaled ambroxol in the adjunctive treatment of the lower respiratory tract infection induced by Pseudomonas aeruginosa.METHODS A total of 41 patients with lower respiratory tract infection induced by P.aeruginosa were randomly divided into two groups.The control group received the combination therapy of piperacillin/tazobactam and levofloxacin,while the trial group received inhaled ambroxol plus the combination therapy.The course of treatment for both groups was 10-14 d.RESULTS The clinical cure rates of trial group and control group were 65.0%and 33.3%,respectively,and clinical efficacy rates were 85.0% and 66.7%,respectively.The bacterial eradication rates were 75.0% in trial group and 42.9% in control group.The differences in both clinical cure rates and the bacterial eradication rates between the two groups were statistically significant(P0.05),but no significant difference in the clinical efficacy rates.No side effects occured in trial group.CONCLUSION Inhaled ambroxol could help to clear P.aeruginosa and might be an ideal adjunctive therapy for the lower respiratory tract infection induced by P.aeruginosa.